Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584634 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT02584634 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 43 participants.
The verdict
NCT02584634, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
Interventions
- DRUG Avelumab
- DRUG Crizotinib
- DRUG PF-06463922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2022-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584634
The ClinicalTrials.gov registry entry for NCT02584634 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avelumab is the first listed.
NCT02584634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584634 about?
NCT02584634 is a clinical study titled "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)". The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
What is the current status of trial NCT02584634?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2015-12-18. Estimated completion is 2022-07-13.
What interventions are being tested in trial NCT02584634?
The interventions under investigation include: Avelumab (DRUG), Crizotinib (DRUG), PF-06463922 (DRUG).
Who is sponsoring clinical trial NCT02584634?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.